Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7014
In June 2010, the Israeli Licensee entered into an exclusive, royalty-bearing out-licensing arrangement with Cypress Bioscience with regard to BL-1020, covering the United States, Canada and Mexico, which became effective in August 2010. The Licensee received an upfront fee of $30.0 million from Cypress Bioscience upon the effectiveness of the agreement.
BL-1020 is for the treatment of schizophrenia.
IPSCIO Record ID: 6748
IPSCIO Record ID: 7006
BL-1020 for the treatment of schizophrenia is one of the Licensee's lead therapeutic candidates in clinical development. BL-1020 for the treatment of schizophrenia.
IPSCIO Record ID: 203252
and a non-exclusive license, with the right to grant sublicenses, through multiple tiers, under Product Inventions, to use any Product Inventions for the pre-commercialization, manufacture and commercialization of products other than the Products in the Licensee Territory;
and an exclusive license, with the right to grant sublicenses, through multiple tiers, to use Licensor Regulatory Data to Pre-Commercialize, Commercialize or manufacture the Products in the Licensee Territory, including the right to use any and all such Licensor Regulatory Data in any Regulatory Filings.
BL-1020 (perphenazine gamma-aminobutyrate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia, it's an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist.
IPSCIO Record ID: 4271